Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Type 2 Idiopathic Macular Telangiectasia
NCT00504400Phase 2Completed
- Sponsor
- University Hospital Bonn
- Start
- Aug 2007
- Primary completion
- Jun 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in idiopathic macular telangiectasia type 2 (MacTel2), sponsored by University Hospital Bonn. Started Aug 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
idiopathic macular telangiectasia type 2 (MacTel2)
Beyond the preview
Go deeper on NCT00504400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504400.